The key role of hydroxylation for the cytostatic activity and selectivity of cyclophosphamide Peter HilgardNorbert Brock OriginalPaper Pages: 131 - 132
Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide Ulf NiemeyerJürgen EngelWerner Weigert OriginalPaper Pages: 133 - 139
Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide) David S. AlbertsJanine G. EinspahrSydney E. Salmon OriginalPaper Pages: 141 - 148
Observations on the effects of cyclophosphamide, phosphoramide mustard and some activated oxazaphosphorines on murine L1210 leukemia Daniel S. ZaharkoJoseph M. CoveyGerhardt Hörpel OriginalPaper Pages: 149 - 154
Antiproliferative activity of 2-[N,N-bis-2-chloroethyl}-amino]-4-[2-sulfonato-ethylthio]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide cyclohexamine (ASIA Z 7557, INN mafosfamide) against human and murine tumor cells in vitro John S. KovachPhyllis A. Svingen OriginalPaper Pages: 155 - 159
Macromolecular DNA-damage in murine and human leukemic and lymphoid cells after in vitro exposure to ASTA Z 7557 (INN mafosfamide) Rainhardt OsiekaR. PannenbäckerCarl Gottfried Schmidt OriginalPaper Pages: 161 - 168
Antineoplastic activity of ASTA Z 7557 (NSC-345842, INN mafosfamide) on transplantable murine tumors Ghanem AtassiPeter HilgardJoarg Pohl OriginalPaper Pages: 169 - 173
Antineoplastic activity of ASTA Z 7557 (INN mafosfamide) in transplanted and autochthonous experimental rodent tumors W. Jens ZellerMartin R. BergerJochen Schuhmacher OriginalPaper Pages: 175 - 180
A comparative study of therapeutic activity, myelotoxicity and DNA damage in the bone marrow of mice after cyclophosphamide and ASTA Z 7557 (INN mafosfamide) Martin R. BergerPhilip BedfordManfred Kaufmann OriginalPaper Pages: 181 - 186
ASTA Z 7557 (INN mafosfamide) for the in vitro treatment of human leukemic bone marrows Luc DouayNorbert Claude GorinGérard Duhamel OriginalPaper Pages: 187 - 190
Preclinical evaluation of toxicity and therapeutic efficacy of a stabilized cytostatic metabolite of cyclophosphamide (ASTA Z 7557, INN mafosfamide) Hans Otto KleinPremaratne Dias WickramanayakeClaudia Coerper OriginalPaper Pages: 191 - 199
Experimental toxicology of ASTA Z 7557 (INN mafosfamide) Joerg PohlPeter HilgardHans-Juergen Zechel OriginalPaper Pages: 201 - 206
Comparative effects of ASTA Z 7557 (INN mafosfamide) and cyclophosphamide on hematopoiesis in mice M. R. NowrousianC. G. Schmidt OriginalPaper Pages: 207 - 213
Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice John D. RobertsMiles P. HackerIrwin H. Krakoff OriginalPaper Pages: 215 - 220
Evaluation of various cytostatic drugs as local immunotherapeutic agents R. J. ScheperA. VosG. H. Boerrigter OriginalPaper Pages: 221 - 225
Inhibition of human B lymphocyte differentiation by a stable metabolite of cyclophosphamide (ASTA Z 7557, INN mafosfamide) Andrzej GorskiGrażyna Korczak-Kowalska OriginalPaper Pages: 227 - 229
Effect of ASTA Z 7557 (INN mafosfamide) a precursor of 4-hydroxy-cyclophosphamide on human T-lymphocytes' Fc-receptors and immunoregulatory functions Johannes G. SaalMartin HadamPeter Fritz OriginalPaper Pages: 231 - 235
Toxicity of ASTA Z 7557 (INN mafosfamide) to normal- and leukemic stem cells: Implications for autologous bone marrow transplantation Anton HagenbeekAnton C. M. Martens OriginalPaper Pages: 237 - 243
Autologous bone marrow transplantation for acute leukemia using transplant chemopurified with metabolite of oxazaphosphorines (ASTA Z 7557, INN mafosfamide) P. HervéJ. Y. CahnA. Peters OriginalPaper Pages: 245 - 252
The influence of the protector thiol L-cystein on the toxic and therapeutic responses of stabilized “activated” cyclophosphamide (4-(S-ethanol)-sulfido-cyclophosphamide) Georg VoelckerPeter LaberHans-Jürgen Hohorst OriginalPaper Pages: 253 - 259
